Contact

Our portfolio

AMI Pharma

AMI Pharma develops therapeutics compounds for Type 1 Diabetes and autoimmune diseases. Their research, based on IP from Amsterdam UMC and Wageningen University & Research, aims to bring new treatments to the clinical trials. AMI Pharma leverages extensive pre-clinical and clinical data to advance their therapeutic pipeline.

  • Institute: Amsterdam UMC
Industry: Diabetes, Metabolic Disorders, Therapeutics
  • Founding year: 2022
Visit website

Want to get in contact about AMI Pharma?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
PacingCure
Developing gene therapy solutions for heart rhythm disorders.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Deep Sleep Technologies
Enhancing deep sleep through real-time, non-invasive brainwave stimulation using adaptive, science-backed algorithms.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
PacingCure
Developing gene therapy solutions for heart rhythm disorders.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Deep Sleep Technologies
Enhancing deep sleep through real-time, non-invasive brainwave stimulation using adaptive, science-backed algorithms.
Explore full AAV portfolio
Contact